BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31771883)

  • 1. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma.
    Harabuchi S; Kosaka A; Yajima Y; Nagata M; Hayashi R; Kumai T; Ohara K; Nagato T; Oikawa K; Ohara M; Harabuchi Y; Ohkuri T; Kobayashi H
    Biochem Biophys Res Commun; 2020 Feb; 522(2):408-414. PubMed ID: 31771883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma.
    Kwon M; Nam GH; Jung H; Kim SA; Kim S; Choi Y; Lee YS; Cho HJ; Kim IS
    Cancer Lett; 2021 Dec; 522():198-210. PubMed ID: 34571082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
    Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
    Ye G; Zhang J; Zhang C
    Aging (Albany NY); 2021 Aug; 13(16):20793-20807. PubMed ID: 34459788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice.
    Brand M; Laban S; Theodoraki MN; Doescher J; Hoffmann TK; Schuler PJ; Brunner C
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
    Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
    Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin Effects on FOXP3
    Amin D; Richa T; Mollaee M; Zhan T; Tassone P; Johnson J; Luginbuhl A; Cognetti D; Martinez-Outschoorn U; Stapp R; Solomides C; Rodeck U; Curry J
    Laryngoscope; 2020 Sep; 130(9):E490-E498. PubMed ID: 31593308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    de la Iglesia JV; Slebos RJC; Martin-Gomez L; Wang X; Teer JK; Tan AC; Gerke TA; Aden-Buie G; van Veen T; Masannat J; Chaudhary R; Song F; Fournier M; Siegel EM; Schabath MB; Wadsworth JT; Caudell J; Harrison L; Wenig BM; Conejo-Garcia J; Hernandez-Prera JC; Chung CH
    Clin Cancer Res; 2020 Mar; 26(6):1474-1485. PubMed ID: 31848186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.
    Yoshimoto K; Kishida T; Nakano H; Matsui M; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Takeuchi M; Hisa Y; Mazda O
    J Immunother; 2011 Mar; 34(2):139-48. PubMed ID: 21304406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
    Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
    Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
    [No Abstract]   [Full Text] [Related]  

  • 18. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
    Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
    Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mechanism of cisplatin resistance in head and neck squamous cell carcinoma involving extracellular vesicles and a copper transporter system.
    Ogawa T; Ono K; Ryumon S; Kawai H; Nakamura T; Umemori K; Yoshida K; Kanemoto H; Obata K; Yoshioka N; Okui T; Okamoto K; Nagatsuka H; Ibaragi S
    Head Neck; 2024 Mar; 46(3):636-650. PubMed ID: 38164660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulsed Radiation Therapy With Concurrent Cisplatin Results in Superior Tumor Growth Delay in a Head and Neck Squamous Cell Carcinoma Murine Model.
    Meyer K; Krueger SA; Kane JL; Wilson TG; Hanna A; Dabjan M; Hege KM; Wilson GD; Grills I; Marples B
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):161-9. PubMed ID: 27511853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.